S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
3 Safe Earnings Plays for a Risk-Off Market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Micron to bring microchip plant to upstate New York
WTO predicts trade growth to slow next year amid crises
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Live Updates: Russia-Ukraine War
Don't Give Up on These Q3 Losers
The U.S. Solution to China's Copper Grab (Ad)
Stocks rise in extended rally, clawing back more ground
European shares fall as selling kicks in after recent gains
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
3 Safe Earnings Plays for a Risk-Off Market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Micron to bring microchip plant to upstate New York
WTO predicts trade growth to slow next year amid crises
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Live Updates: Russia-Ukraine War
Don't Give Up on These Q3 Losers
The U.S. Solution to China's Copper Grab (Ad)
Stocks rise in extended rally, clawing back more ground
European shares fall as selling kicks in after recent gains
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
3 Safe Earnings Plays for a Risk-Off Market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Micron to bring microchip plant to upstate New York
WTO predicts trade growth to slow next year amid crises
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Live Updates: Russia-Ukraine War
Don't Give Up on These Q3 Losers
The U.S. Solution to China's Copper Grab (Ad)
Stocks rise in extended rally, clawing back more ground
European shares fall as selling kicks in after recent gains
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
3 Safe Earnings Plays for a Risk-Off Market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Micron to bring microchip plant to upstate New York
WTO predicts trade growth to slow next year amid crises
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Live Updates: Russia-Ukraine War
Don't Give Up on These Q3 Losers
The U.S. Solution to China's Copper Grab (Ad)
Stocks rise in extended rally, clawing back more ground
European shares fall as selling kicks in after recent gains
OTCMKTS:TCNNF

Trulieve Cannabis - TCNNF Stock Forecast, Price & News

$9.15
+0.47 (+5.41%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.68
$9.25
50-Day Range
$8.50
$14.78
52-Week Range
$8.29
$34.75
Volume
273,062 shs
Average Volume
318,340 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.94
TCNNF stock logo

About Trulieve Cannabis (OTCMKTS:TCNNF) Stock

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. It cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. The company produces flower, edible, vaporizer cartridge, concentrate, topical, capsule, tincture, dissolvable powder, and nasal spray products under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One brands. As of March 16, 2022, it operated 162 dispensaries, which included 113 dispensaries in Florida, 19 affiliated dispensaries in Pennsylvania, 17 dispensaries in Arizona, five dispensaries in California, three dispensaries in Maryland, two dispensaries in Massachusetts, two dispensaries in West Virginia, and one dispensary in Connecticut. Trulieve Cannabis Corp. also operated cultivation and processing facilities in Arizona, Colorado, Florida, Maryland, Massachusetts, Nevada, Pennsylvania, and West Virginia. The company was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Quincy, Florida.

Receive TCNNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trulieve Cannabis and its competitors with MarketBeat's FREE daily newsletter.

TCNNF Stock News Headlines

Trulieve Announces October 2022 Event Participation
Surprisingly, Aside from $500+ Megadeals, 2022 Is A Normal M&A Year
4 Cannabis Stocks To Watch For September 2022
Trulieve Announces September 2022 Event Participation
Trulieve Cannabis Corp. (OTC: TCNNF)
Can Trulieve Recover From the Harvest Deal?
See More Headlines
Receive TCNNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trulieve Cannabis and its competitors with MarketBeat's FREE daily newsletter.

TCNNF Company Calendar

Last Earnings
11/15/2021
Today
10/05/2022
Next Earnings (Estimated)
11/14/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:TCNNF
Fax
N/A
Employees
6,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.93
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+434.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Ms. Kimberly Rivers (Age 44)
    Founder, Chairman & CEO
    Comp: $4.3M
  • Mr. Alex D'Amico CPA (Age 47)
    Chief Financial Officer
    Comp: $880.21k
  • Mr. Eric Raymond Powers III (Age 53)
    J.D., Chief Legal Officer & Corp. Sec.
    Comp: $720.21k
  • Mr. Steven Mathew White (Age 48)
    Pres
  • Ms. Rebecca L. Young (Age 41)
    VP & Chief Accounting Officer
  • Mr. Nilyum Jhala
    Chief Technology Officer
  • Mr. Jason Barry Pernell (Age 44)
    Chief Information Officer
  • Ms. Christine Hersey
    Director of Investor Relations
  • Mr. Robert Kremer
    Exec. Director of Corp. Communications
  • Ms. Victoria Walker (Age 37)
    Director of Marketing & Community Relations













TCNNF Stock - Frequently Asked Questions

Should I buy or sell Trulieve Cannabis stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trulieve Cannabis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TCNNF shares.
View TCNNF analyst ratings
or view top-rated stocks.

What is Trulieve Cannabis' stock price forecast for 2022?

5 equities research analysts have issued twelve-month target prices for Trulieve Cannabis' shares. Their TCNNF share price forecasts range from $24.00 to $57.00. On average, they anticipate the company's stock price to reach $42.93 in the next year. This suggests a possible upside of 369.2% from the stock's current price.
View analysts price targets for TCNNF
or view top-rated stocks among Wall Street analysts.

How have TCNNF shares performed in 2022?

Trulieve Cannabis' stock was trading at $26.01 at the beginning of the year. Since then, TCNNF stock has decreased by 64.8% and is now trading at $9.15.
View the best growth stocks for 2022 here
.

Are investors shorting Trulieve Cannabis?

Trulieve Cannabis saw a increase in short interest in August. As of August 31st, there was short interest totaling 376,200 shares, an increase of 50.7% from the August 15th total of 249,700 shares. Based on an average daily volume of 542,000 shares, the short-interest ratio is presently 0.7 days.
View Trulieve Cannabis' Short Interest
.

When is Trulieve Cannabis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TCNNF earnings forecast
.

How were Trulieve Cannabis' earnings last quarter?

Trulieve Cannabis Corp. (OTCMKTS:TCNNF) posted its quarterly earnings data on Monday, November, 15th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.27 by $0.13.

What guidance has Trulieve Cannabis issued on next quarter's earnings?

Trulieve Cannabis issued an update on its FY 2022 earnings guidance on Friday, September, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.25 billion-$1.30 billion, compared to the consensus revenue estimate of $1.34 billion.

What is Trulieve Cannabis' stock symbol?

Trulieve Cannabis trades on the OTCMKTS under the ticker symbol "TCNNF."

How do I buy shares of Trulieve Cannabis?

Shares of TCNNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trulieve Cannabis' stock price today?

One share of TCNNF stock can currently be purchased for approximately $9.15.

How many employees does Trulieve Cannabis have?

The company employs 6,900 workers across the globe.

How can I contact Trulieve Cannabis?

Trulieve Cannabis' mailing address is 6749 Ben Bostic Road, Quincy, FL 32351. The official website for the company is www.trulieve.com. The company can be reached via phone at (850) 480-7955.

This page (OTCMKTS:TCNNF) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.